Leary, Alexandra
Estévez-García, Purificación
Sabatier, Renaud
Ray-Coquard, Isabelle
Romeo, Margarita
Barretina-Ginesta, Pilar
Gil-Martin, Marta
Garralda, Elena
Bosch-Barrera, Joaquim
Morán, Teresa
Martin-Martorell, Paloma
Nadal, Ernest
Gascón, Pere
Rodon, Jordi
Lizcano, Jose M
Muñoz-Guardiola, Pau
Fierro-Durán, Gemma
Pedrós-Gámez, Oriol
Pérez-Montoyo, Héctor
Yeste-Velasco, Marc
Cortal, Marc
Pérez-Campos, Antonio
Alfon, Jose
Domenech, Carles
Pérez-Fidalgo, Alejandro
Oaknin, Ana
Funding for this research was provided by:
Centro para el Desarrollo Tecnológico Industrial (INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061, INNOGLOBAL/20171061)
European Regional Development Fund (PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042, PI18/0042)
Ministerio de Ciencia e Innovación (RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1, RETOS RTC-2017-6261-1)
Article History
Received: 2 January 2024
Accepted: 10 June 2024
First Online: 22 July 2024
Change Date: 29 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12885-024-12700-0
Declarations
:
: The study was initially registered on 19/09/2016 and approved in Spain by the National Competent Authority (AEMPS: Agencia Española de Medicamentos y Productos Sanitarios) and by the Ethics Committee “Comité de Ética de la Investigación con medicamentos (CEIm)” from Hospital Universitari Vall d’Hebrón (Barcelona, Spain), and in France by the National Competent Authority (ANSM: Agence nationale de sécurité du médicament et des produits de santé) and by the Ethics Committee “Comité de Protection des Personnes SUD-EST II” from Groupemet Hospitalier Est (Bron, France). The study was performed in accordance with the Declaration of Helsinki, the International Conference on Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, Good Clinical Practice, and local laws. All patients provided written informed consent. The trial is registered with the USA Registry of Clinical Trials (ClinicalTrials.gov) with the trial ID number NCT03366480. All other authors declare no competing interests.
: This study does not contain individual data of person.
: A.L. declares advisory board fees and travel support from AstraZeneca, advisory board fees from Clovis, Gridstone, AbilityPharma and Pfizer, grant support and advisory board fees from GamaMabs, and grant support from Merus and Sanofi. R.S. declares research grants from Astrazeneca, consulting fees from GSK, Seagen, Eisai, Novartis, and Clovis Oncology, and non-financial support from MSD, Novartis, and GSK. I.R.C. declares self-honoraria from Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersena, Merck Sereno, Novartis, Amgen, Macrogenics, Tesaro and Clovis and consulting fees from Abbvie, Agenus, Advaxis, BMS, ESAÏ, Daichi, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding (self) from MSD, Roche and BMS and other institution fees from GSK, MSD, Roche, BMS and Astrazeneca. M.R. declares advisory board GSK, speaker bureau AZ, travel grants AZ, MSD, dedication activities AZP.B.G. declares advisory Board and travel expenses from: Astra Zeneca, Clovis, GSK, MSD, Eisai and Pharmamar M.G.M. has nothing to disclose related to this job. Speaking: MSD, Astra Zeneca; Registration and attending scientific meetings: MSD, Clovis, GSKE.G. declares consulting fees from Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Thermo Fisher, MabDiscovery, Anaveon, F-Star Therapeutics, Hengrui, Sanofi, Incyte, Medscape. Grants or contracts from Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene and Janssen. Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck Sharp & Dohme, Roche, Thermo Fisher, Novartis and SeaGen. Holds stocks from 1TRIALSP. Is employed by NEXT Oncology and PI or Co-PI institutional from Adaptimmune LLC, Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Bicycletx Ltd, BioInvent International AB, Biontech SE, Biontech Small Molecules Gmbh, Boehringer Ingelhem International Gmbh, Catalym Gmbh, Cyclacel Biopharmaceuticals, Cytovation AS, Cytomx, F.Hoffmann La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hifibio Therapeutics, Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Incyte Corporation, Incyte Europe Sàrl, Janssen-Cilag International NV, Janssen-Cilag SA, Laboratorios Servier SL, Medimmune Llc, Merck & Co, Inc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Pfizer Slu, Relay Therapeutics, Replimmune, Ribon Therapeutics, Ryvu Therapeutics SA, Seattle Genetics Inc, Sotio AS, Sqz Biotechnologies, Symphogen A/S, Taiho Pharma Usa Inc and T-Knife GmbhJ.B.B. has received consulting fees and honoraria from Roche, Pfizer, AstraZeneca, Vifor, Sanofi, MSD and BMS. T.M. declares consulting/advisory role fees by Roche, Bristol Myers, Boeringher, Astra Zeneca. Research Funding Grant by Kyowa Kirin and Janssen, all of them unrelated with the current workE.N. declares the following financial Interests: Invited Speaker, Personal from Amgen, AstraZeneca, Bristol Myers Squibb, Illumina, Daiichi, Janssen, Lilly, Merck Sharp Dohme, Pfizer, Qiagen, Roche, Sanofi, Takeda; Advisory Board, Personal from Amgen, AstraZeneca, Boehringer, Ingelheim, Bristol Myers Squibb, Daiichi SankyoJanssen, Lilly, Merck Serono, Merck Sharp Dohme, Pfizer, Pierre Fabre, Regeneron, Roche, Sanofi, Takeda and Qiagen. Funding, Personal and Institutional, No financial interest from Bristol Myers Squibb (funded a clinical trial), Merck Serono (funded a clinical trial) and Roche (funded a clinical trial). Non-Financial Interests, Advisory Role from Apollomics, Pfizer and Roche. Member of the Steering Committee of the Spanish Lung Cancer Group (GECP). J.R. reports non-financial support and reasonable reimbursement for travel from European Society for Medical Oncology and Loxo Oncology; receiving consulting and travel fees from Ellipses Pharma, Molecular Partners, IONCTURA, Sardona, Mekanistic, Amgen, Merus, MonteRosa, Aadi and Bridgebio (including serving on the scientific advisory board); Consulting fees from Vall d’Hebron Institute of Oncology/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, Boxer Capital, LLC, Tang Advisors, LLC and Guidepoint, receiving research funding from Blueprint Medicines, Merck Sharp & Dohme, Hummingbird, AstraZenneca, Yingli, Vall d’Hebron Institute of Oncology/Cancer Core Europe; and serving as investigator in clinical trials with Cancer Core Europe, Symphogen, BioAlta, Pfizer, Kelun-Biotech, GlaxoSmithKline, Taiho, Roche Pharmaceuticals, Hummingbird, Yingli, Bicycle Therapeutics, Merus, AadiBioscience, ForeBio, Loxo Oncology, Hutchinson MediPharma, Ideaya, Amgen, Tango Therapeutics, Mirati, Linnaeus Therapeutics, MonteRosa, Kinnate, Yingli, Debio, BioTheryX, Storm Therapeutics, Beigene, MapKure, Relay, Novartis, FusionPharma, C4 Therapeutics, Scorpion Therapeutics, Incyte, Fog Pharmaceuticals, Tyra, Nuvectis Pharma. J.M.L. declares to be the chairman of the Scientific Advisory Board from AbilityPharma, and that holds stocks from Ability Pharmaceuticals P.M.G. declares that was an employee of Ability Pharmaceuticals and holds stocks from the company G.F.D. declares that is an employee of Ability Pharmaceuticals and holds stocks from the company O.P.G. declares that is an employee of Ability PharmaceuticalsH.P.M. declares that is an employee of Ability Pharmaceuticals and holds stocks from the company M.Y.V. declares that was an employee of Ability Pharmaceuticals and holds stocks from the company M.C. declares that is an employee of Ability Pharmaceuticals and holds stocks from the company A.P.C declares that is the chairman of the Clinical Advisory Board of Ability Pharmaceuticals and that holds stocks from the companyJ.A. declares that was an employee of Ability Pharmaceuticals and holds stocks from the company * C.D. declares that is the CEO, CSO and co-founder of Ability Pharmaceuticals and that holds stocks from the companyA.P.F. declares speaker bureau from Astrazeneca, Clovis, GSK, Pharmamar, MSD, Pharma&. Advisory from Astrazeneca, Eisai, MSD, AbilityPharma, Pharmamar, Clovis. Travel expenses from Astrazeneca, Pharmamar, GSK. Grants to my institution from Astrazeneca, GSK and Pharmamar. A.O. reports personal fees for advisory board membership from Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, Exelisis, EMD Serono, F. Hoffmann-La Roche, Genmab, GSK, ImmunoGen, Itheos, Merck Sharps & Dohme de España, SA, Mersana Therapeutics, Novocure, OneXerna Therapeutics, Inc., PharmaMar, Regeneron, Sattucklabs, Seagen and Sutro Biopharma; personal fees for travel/accommodation from AstraZeneca, PharmaMar and Roche; institutional funding from Abbvie Deutschland, Advaxis Inc., Aeterna Zentaris, Amgen, Aprea Therapeutics AB, Bristol Myers Squibb, Clovis Oncology Inc, EISAI limited LTD, F. Hoffmann –La Roche LTD, Immunogen Inc, Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc, PharmaMar SA, Regeneron Pharmaceuticals and Tesaro Inc.; non-remunerated roles at ESMO (member, Officer, Co-Chair of the ESMO Gynaecological Cancers Congress 2023-2025, Chair of the Gynaecological Track ESMO 2019, Scientific Track Member Gynaecological Cancers ESMO 2018, ESMO 2020, ESMO 2022, member of the Gynaecological Cancers Faculty and Subject Editor for the Gynaecological Clinical Practice Guidelines); a non-remunerated role at GCIG (member and Cervix Cancer Chair on behalf of GEICO); and membership of ASCO, GOG and SEOM.All other authors do not have any kind of competing interest.